2022 ESC速递：心力衰竭相关临床研究解读

详细信息

收稿日期: 2022-09-20

刊出日期: 2022-10-13

2022 ESC express: Interpretation of new clinical trials on heart failure

- Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

More Information

Received Date: 20 September 2022

Publish Date: 13 October 2022

摘要: 2022年8月，在西班牙巴塞罗那召开的ESC大会发布了DELIVER研究、PERSPECTIVE研究及ADVOR研究等心力衰竭重磅研究结果，给心力衰竭的治疗带来了新的循证医学证据。
- ESC速递 /
- 心力衰竭 /
- DELIVER研究
Abstract: In August 2022, the ESC Conference held in Barcelona, Spain, released the latest results of DELIVER, PERSPECTIVE, ADVOR clinical trial about heart failure, bringing new concept of evidence-based medical treatment to the heart failure.
- ESC express /
- heart failure /
- DELIVER trial

[1]	Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction[J]. N Engl J Med, 2022, 387(12): 1089-1098. doi: 10.1056/NEJMoa2206286
[2]	McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36): 3599-3726.
[3]	中国心力衰竭中心联盟专家委员会. 心力衰竭SGLT2抑制剂临床应用的中国专家共识[J]. 临床心血管病杂志, 2022, 38(8): 599-605.
[4]	Jhund PS, Kondo T, Butt JH, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER[J]. Nat Med, 2022, 28(9): 1956-1964. doi: 10.1038/s41591-022-01971-4
[5]	Anker SD, Butler J, Filippatos G, et al. EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction[J]. N Engl J Med, 2021, 385(16): 1451-1461. doi: 10.1056/NEJMoa2107038
[6]	Mullens W, Dauw J, Martens P, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload[J]. N Engl J Med, 2022. doi:10.1056/NEJMoa2203094.